Auauniversity

Dr Nitti and Dr. Daneshmand discuss the AUA Update Series Article titled "Update on Medical and Surgical Management of Advanced Testis Cancer" This episode will describe and explain the current recommendations for imaging; indications for post-chemotherapy retroperitoneal lymph node dissection; the IGCCCG (International Germ Cell Cancer Consensus Group) risk classification; and pros and cons of 3 cycles of cisplatin, etoposide and bleomycin vs 4 cycles of etoposide and cisplatin EP for IGCCCG good risk disease.

AUA2017 Court is in Session: Sepsis after Mini PNCL by AUAUniversity

Dr. Tanya D. Dorff presentation on Treatment Sequencing and Combinatorial Strategies in CRPC Acknowledgements The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support: Astellas AbbVie Genomic Health Sanofi Genzyme Tolmar Pharmaceuticals, Inc. CRPCProstate CancerAUA

Dr. Adam S. Kiebel presents a presentation on the 2017 AUA CRPC Guideline. Dr. Kibel is Chief of Urologic Surgery at both the Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston, Massachusetts. In addition, he is Elliot Carr Cutler Professor of Surgery at Harvard University School of Medicine, Chairman of the Harvard Program in Urology Residency Program (Longwood) and Co-Leader of the Prostate Cancer Program for Dana Farber/Harvard Cancer Center. Dr Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and his fellowship at the Brady Urologic Institute at Johns Hopkins in Baltimore, Maryland. Acknowledgements The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support: Astellas AbbVie Genomic Health Sanofi Genzyme Tolmar Pharmaceuticals, Inc.

AUA2017 Court is in Session: Myocardial Infarction on Androgren Replacement Therapy by AUAUniversity

Court is in Session: Colostomy after Robotic Prostatectomy Speaker: Christopher P. Evans, MD

AUA2017 Take Home Messages: BPH/LUTS - Minimally Invasive Surgery - Quality by AUAUniversity

AUA2017 Take Home Messages: Bladder Cancer - Transplantation - Female Urology by AUAUniversity

AUA2017 Take Home Messages: Pediatrics | Penile/Urethral Cancer | Kidney Cancer by AUAUniversity

AUA2017 Take Home Messages: Infertility/Andrology | Outcomes | Sexual Dysfunction by AUAUniversity

AUA2017 Take Home Messages: Prostate Cancer, Basic Sciences, and Trauma/Reconstruction by AUAUniversity

Bladder Cancer Immunotherapy Series: Complex Patient Cases by AUAUniversity

PSA Screening changes and USPSTF Recommendations by AUAUniversity

Bladder Cancer Immunotherapy Series: AUA Guideline by AUAUniversity

Low Testosterone by AUAUniversity

SUFU Clinical Care Pathway by AUAUniversity

Bladder Cancer Immunotherapy Series: Immunotherapy: From Research to Practice #1 by AUAUniversity

Core Curriculum Video Abstract Request by AUAUniversity

The goal of this knowledge-based activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of bladder cancer and to increase their ability to improve patient outcomes and the management of adverse events. Educational grants provided by the following corportations: AstraZeneca, Bristol-Myers Squibb, Genentech, Merck

Transgender; What Every Urologist Should Know by AUAUniversity